--- title: "J147: Dosing & Vendor Prices — BodyHackGuide" description: "J147: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "J147" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "J147", "description": "J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical. The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554). The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628). The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619). Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market.", "url": "https://www.bodyhackguide.co/compound/j-147", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "99.99", "highPrice": "99.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "99.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/j-147/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "J147", "description": "J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical. The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554). The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628). The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619). Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market.", "lastReviewed": "2026-09-07T04:46:52.351Z", "url": "https://www.bodyhackguide.co/compound/j-147", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "J147", "alternateName": [ "J-147", "J 147", "Curcumin-derived phenyl hydrazide", "N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-((3-methoxyphenyl)methylideneamino)acetamide" ], "description": "J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical. The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554). The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628). The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619). Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market.", "activeIngredient": "J147", "administrationRoute": "Oral, Intravenous infusion", "mechanismOfAction": "The molecular target of J147 is the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase increases intracellular calcium, which produces sustained calcium/calmodulin-dependent protein kinase kinase beta (CAMKK2) dependent activation of the AMPK and mTOR pathway, a canonical longevity mechanism; in mice this prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Downstream, J147 and a structurally distinct analog raised acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1, increasing histone H3K9 acetylation and preserving mitochondrial homeostasis in rapidly aging SAMP8 mice (PMID: 31742554). The original characterization also reported induction of nerve growth factor and brain-derived neurotrophic factor and preservation of synaptic proteins in transgenic Alzheimer disease mice (PMID: 22194796; PMID: 23673233).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is J147 used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical. The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554). The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628). The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619). Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market." } }, { "@type": "Question", "name": "What forms does J147 come in?", "acceptedAnswer": { "@type": "Answer", "text": "J147 is available in capsule form." } }, { "@type": "Question", "name": "How much does J147 cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $99.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare J147 vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fj-147) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. J147 [Where to buy J147](/buy/j-147) [J147 coupon codes](/coupons/j-147) [J147 protocol](/protocol/j-147) [Alternatives to J147](/alternatives-to/j-147) [J147 side effects](/side-effects/j-147) 1. [Home](/) 3. [Compounds](/compare) 5. J147 ![J147 molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # J147 Nootropics Phase 2 Download PDF Also known as: J-147, J 147, Curcumin-derived phenyl hydrazide, N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-((3-methoxyphenyl)methylideneamino)acetamide J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. Half-Life: Not established in humans; the phase 1 study measured terminal half-life but has not reported results (NCT03838185). After oral dosing in mice, half-life was about 1.5 hours in plasma and 2.5 hours in brain, with oral bioavailability calculated at 28 percent and a brain to blood ratio of about 0.5 (PMID: 23673233). Route: Oral, Intravenous infusion MW: 350.34 g/mol CAS: 1146963-51-0 Last reviewed: Sep 7, 2026 [ Nootropics Category ](/wiki#cat-nootropics) Phase 2 Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $99.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/j-147/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism The molecular target of J147 is the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase increases intracellular calcium, which produces sustained calcium/calmodulin-dependent protein kinase kinase beta (CAMKK2) dependent activation of the AMPK and… Half-Life Not established in humans; the phase 1 study measured terminal half-life but has not reported results (NCT03838185). After oral dosing in mice, half-life was about 1.5 hours in plasma and 2.5 hours in brain, with oral bioavailability calculated at 28 percent and a brain to blood ratio of about 0.5 (PMID: 23673233). Routes Oral Intravenous infusion Potential Benefits Facilitated memory in normal rodents and prevented loss of synaptic proteins and cognitive decline in transgenic Alzheimer disease mice (PMID: 22194796) Rescued spatial navigational memory and contextual fear conditioning in 20-month-old APP/PS1 mice treated after pathology was already advanced, with induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233) Prevented age-associated drift in the hippocampal transcriptome and plasma metabolome in mice and extended lifespan in Drosophila through ATP synthase and the AMPK pathway (PMID: 29316249) Reduced cognitive decline and metabolic and transcriptional markers of aging in rapidly aging SAMP8 mice (PMID: 31742554) Reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage in rat models of ischemic stroke (PMID: 35309561) Improved neurofunctional recovery and reduced acute neurodegeneration after controlled cortical impact injury in mice (PMID: 39245209) ### Overview J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical. The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554). The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628). The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619). Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market. ### Potential Research Fields Alzheimer disease Mitochondrial ATP synthase Brain aging Neuroprotection ## Chemical Information IUPAC Name Not yet available CAS Number 1146963-51-0 Molecular Formula C18H17F3N2O2 Molecular Mass 350.34 g/mol ![J147 molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/25229652/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/25229652) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications None established in humans. The published phase 1 protocol excluded volunteers with clinically significant cardiovascular, neurological, psychiatric, hepatic or renal disease, required them to avoid grapefruit and Seville oranges, and excluded anyone who had taken known hepatic or renal clearance altering agents in the preceding 30 days, which indicates sponsor concern about metabolic interactions (NCT03838185). Mechanism-based caution: the target is the mitochondrial alpha-F1-ATP synthase and the compound works by modest inhibition of that enzyme (PMID: 29316249), so it is a metabolic intervention rather than a neutral supplement, and cell work shows mitochondrial effects at high concentrations (PMID: 25364619). No pregnancy, lactation or drug interaction data exist in humans. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $99.99 Best $/mg — Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK J-147 capsules (60) capsule 60 capsules ● In Stock $99.99 BEST — — [Buy](https://disguisedalpha.com/product/j-147/?coupon=reddit) Get J147 Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $99.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with J147. [Sign in](/auth) Current low $99.99 as of Sep 7, 2026 7-day low $99.99 30-day low $99.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling J147 [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $99.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) [ View Full Dosage Guide → Protocols, calculator & safety for J147 ](/guides/dosage/j-147) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $99.99 [Buy Now](https://disguisedalpha.com/product/j-147/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established in humans; the phase 1 study measured terminal half-life but has not reported results (NCT03838185). After oral dosing in mice, half-life was about 1.5 hours in plasma and 2.5 hours in brain, with oral bioavailability calculated at 28 percent and a brain to blood ratio of about 0.5 (PMID: 23673233). Molecular Weight 350.34 g/mol Administration Oral, Intravenous infusion CAS Number 1146963-51-0 Trial Phase Phase 2 0 [Full Dosage Guide](/guides/dosage/j-147)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is J147 used for in research? J147 is a synthetic phenyl hydrazide derived from curcumin, made at the Salk Institute for Biological Studies. It came out of a screening strategy that deliberately avoided the amyloid hypothesis: instead of selecting for affinity to one disease-specific target, the group screened compounds against several cell culture models of age-associated pathology. The molecule that emerged was orally active, facilitated memory in normal rodents and prevented the loss of synaptic proteins and cognitive decline in a transgenic Alzheimer disease mouse model (PMID: 22194796). Unlike the racetams on this site, J147 was never a marketed drug anywhere and has always been an investigational compound; consumer-facing material is sold as a research chemical. The molecular target was identified in 2018 as the mitochondrial alpha-F1-ATP synthase subunit ATP5A. Modest inhibition of ATP synthase raises intracellular calcium, which produces sustained CAMKK2-dependent activation of the AMPK and mTOR pathway, a longevity mechanism conserved across species. In mice, J147 prevented age-associated drift in the hippocampal transcriptome and plasma metabolome, and it extended lifespan in Drosophila (PMID: 29316249). Related work found that J147 and a second Salk compound increased acetyl-CoA levels by inhibiting acetyl-CoA carboxylase 1 and reduced cognitive decline and markers of aging in rapidly aging SAMP8 mice (PMID: 31742554). The strongest preclinical result is the treatment design rather than the prevention design. Twenty-month-old APP/PS1 transgenic mice, at a stage where pathology was already advanced, were fed J147 for three months and showed improved spatial navigational memory in the water maze and rescued contextual fear conditioning, alongside induction of nerve growth factor and brain-derived neurotrophic factor (PMID: 23673233). Efficacy has also been reported in rat models of ischemic stroke, where J147 reduced infarct volume and reduced tissue plasminogen activator associated brain hemorrhage (PMID: 35309561), in mouse traumatic brain injury (PMID: 39245209) and in mouse diabetic neuropathy (PMID: 29122628). The animal safety package is unusually detailed for a compound at this stage. Single doses of 2 g/kg in rats and mice produced no acute toxicity, and the Ames test, the hERG assay and CYP3A4 assays were all negative (PMID: 23673233). Because phenyl hydrazides can in principle be metabolized to carcinogenic aromatic amines or hydrazines, the group specifically tested this and found that J147 is not metabolized to those products in human or mouse microsomes or in mouse plasma (PMID: 23582448). A separate panel in a rat hepatoma line put the sustained concentration expected to produce toxicity at about 90 micromolar (PMID: 25364619). Human data are the gap. A phase 1 randomized, double-blind, placebo-controlled single ascending dose study in 64 healthy young and elderly volunteers, sponsored by Abrexa Pharmaceuticals, completed in February 2020 with safety and pharmacokinetics as endpoints, and no results have been posted or published (NCT03838185). A phase 2 study of intravenous J147 combined with endovascular therapy in acute ischemic stroke began recruiting in July 2026 (NCT07430917). J147 is not approved anywhere and remains a research-use-only compound in the United States market. What forms does J147 come in? J147 is available in capsule form. How much does J147 cost? Prices start at $99.99 across 1 verified vendor. How do I compare J147 vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-j-147) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋